Clinical trial
A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
NCT06650007 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 8, 2024
- Completion date
- June 12, 2026
- Enrollment
- 218 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.